Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

CeeNU®Positive

AI Analysis

Summary

Septa Pharmaceuticals has acquired the Canadian rights to CeeNU® (Lomustine), an oncology drug, from Bristol Myers Squibb effective June 29, 2026. The strategic acquisition expands Septa's portfolio in the Canadian healthcare market.

Outcome Details

Septa Pharmaceuticals acquired CeeNU® (Lomustine) from Bristol Myers Squibb, Canada effective June 29, 2026

Importance:5/10

Sentiment:

0.50

M&AAsset acquisitionCanadaOncology

Related Companies

$BMY

Read the original article

Published by PR Newswire Pharma on July 15, 2026 11:00 AM

Read Original